Conciseness

The body is dense with genuinely non-obvious look-up facts Claude cannot reliably know (KEGG pathway IDs like hsa00600, 'm/z 184 for phosphocholine', enzyme-disease pairs, SwissLipids' empty-classification caveat), so most tokens earn their place. Minor redundancy: the SP→apoptosis/neurodegeneration, GP→membrane-remodeling mapping appears in both the Reasoning Strategy and Phase 1, and Key principles 2–4 restate Reasoning Strategy points, and the intro paragraph largely re-covers the frontmatter description. Fits anchor 4 ('efficient; minor instances that could be trimmed') rather than 3 because the padded content is a small fraction of a fact-heavy document, and rather than 5 because the duplication is real.

Actionability

Concrete, copy-paste-ready invocations with parameters and real outputs throughout: 'LipidMaps_search_by_name(query="ceramide")', 'SwissLipids_search(query="PC(16:0/18:1)") → entity_id "SLM:000088148"', and a runnable pandas enrichment snippet in Phase 4. Operational gotchas ('Species-level abbreviations like "Cer(d18:1/16:0)" may return 0 results', 'classification can come back as an empty array [] ... fall back to LIPID MAPS') make the guidance executable rather than descriptive. Not below 5: the only nit is an unused fisher_exact import in the Phase 4 snippet, which does not block execution or coverage of the common case.

Workflow Clarity

A clear Phase 0→4 pipeline is shown as a diagram and then per-phase with concrete steps, and Phase 0 includes explicit fallback loops ('If name search fails, try PubChem', SwissLipids when LIPID MAPS misses, and the empty-classification fallback). Fits anchor 4 ('clear sequence with most checkpoints present; minor validation gaps') rather than 5 because there is no explicit validation of intermediate results in Phases 2–3 beyond the general 'Always verify via HMDB or CTD', and no error-recovery guidance if a KEGG/CTD lookup returns nothing.

Progressive Disclosure

No bundle files exist, and the skill is organized into well-labeled sections (When to Use, Core Tools table, Workflow, Limitations) that make the ~200-line single file navigable. Fits anchor 4 ('good structure; most content appropriately placed') rather than 3 because the inline content (tool table, KEGG pathway table) is genuinely overview-level, but not 5 because some reference-worthy detail (the 8-row KEGG pathway table, the verified SwissLipids examples) would slim the main body if split into a references file, and no one-level-deep reference files are provided to absorb it.

Specificity

Concrete actions are named — 'lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis' — anchored to specific resources ('LIPID MAPS classification, HMDB metabolite data, KEGG/Reactome lipid pathways ..., and PubChem chemical info'). Fits anchor 4 ('lists several specific actions; minor gaps') rather than 5 because the opening action 'Lipid analysis' is generic, 'Reactome' is listed as a source without any concrete Reactome-based action, and the scope of 'PubChem chemical info' is left vague.

Completeness

Both halves are explicit: the 'what' is 'Lipid analysis and lipid-disease associations using LIPID MAPS classification, HMDB metabolite data, KEGG/Reactome lipid pathways ..., and PubChem chemical info', and the 'when' is an explicit trigger clause 'Use for lipid identification, lipid metabolism pathway mapping, and lipid-associated disease analysis (cardiovascular, diabetes, NAFLD)' with concrete trigger phrases. Matches anchor 5 and is clearly above anchor 4, whose 'when' would be less specific.

Trigger Term Quality

Good natural-phrase coverage: users would plausibly say 'lipid identification', 'pathway mapping', 'lipid metabolism', and disease-area terms 'cardiovascular, diabetes, NAFLD', plus class names 'sphingolipid, eicosanoid, steroid, fatty acid'. Fits anchor 4 ('good keyword coverage; a few natural terms missing') rather than 5 because the single most natural user term — 'lipidomics' — is absent (the body's own When-to-Use examples include 'Map my lipidomics results'), along with synonyms like 'lipid profiling' or 'lipid biomarkers'.

Distinctiveness Conflict Risk

Clear niche — lipid-specific classification (LIPID MAPS), lipid pathways, lipid-disease associations — with distinct triggers, but it shares general-purpose databases (HMDB, KEGG, PubChem) with a general metabolomics skill, creating minor overlap risk for queries like 'metabolite disease associations'. Fits anchor 4 ('mostly distinct; minor overlap risk with closely related skills') rather than 5 because the description itself draws no boundary against general metabolomics (the boundary lives only in the body's 'Not this skill' note).